The chemotherapeutic regimen changed in 11 patients from GnP to S-1 or gemcitabine due to GnP-related AEs (pneumonitis, n = 2; sepsis, n = 1; neutrophil count decrease, n = 2; peripheral neuropathy, n = 2; an increase in creatinine, n = 1; lung infection, n = 1; an increased CRP level, n = 1; and fatigue, n = 1). This evidence concerns the gene CRP and peripheral neuropathy.